Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

Bibliographic Details
Main Authors:	Henry, Robert R., Rosenstock, Julio, Logan, Douglas K., Alessi, Thomas R., Luskey, Kenneth, Baron, Michelle A.
Format:	Online
Language:	English
Published:	American Diabetes Association 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747935/

Similar Items

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
by: Ji, Linong, et al.
Published: (2013)

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
by: Mathieu, Chantal, et al.
Published: (2013)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
by: Ridge, T, et al.
Published: (2012)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
by: Simó, Rafael, et al.
Published: (2015)

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
by: Rosenstock, Julio, et al.
Published: (2013)

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
by: Rosenstock, Julio, et al.
Published: (2013)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
by: Rosenstock, Julio, et al.
Published: (2012)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
by: Wolffenbuttel, B. H. R., et al.
Published: (2016)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
by: Tobin, G S, et al.
Published: (2012)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
by: Chiquette, Elaine, et al.
Published: (2012)

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study
by: Matthaei, Stephan, et al.
Published: (2012)

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
by: Inagaki, Nobuya, et al.
Published: (2011)

Long-acting preparations of exenatide
by: Cai, Yunpeng, et al.
Published: (2013)

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
by: McDonell, Amanda L, et al.
Published: (2015)

Evaluation of the stability of exenatide in aqueous solutions
by: Al Assadi, Ali
Published: (2015)

Effect of renal impairment on the pharmacokinetics of exenatide
by: Linnebjerg, Helle, et al.
Published: (2007)

Evolution of Exenatide as a Diabetes Therapeutic
by: Bhavsar, Sunil, et al.
Published: (2013)

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
by: Berg, J K, et al.
Published: (2011)

Research: Treatment: Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
by: Wenten, M, et al.
Published: (2012)

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
by: Östenson, Claes-Göran, et al.
Published: (2013)

Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience
by: Anichini, Roberto, et al.
Published: (2013)

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study
by: Reaney, Matthew, et al.
Published: (2013)

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
by: Davies, Melanie, et al.
Published: (2013)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
by: Alshali, Khalid Z., et al.
Published: (2016)

Exenatide improves glucocorticoid-induced glucose intolerance in mice
by: Zhao, Ruiying, et al.
Published: (2011)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
by: Kyriacou, Angelos, et al.
Published: (2010)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice†
by: Tatarkiewicz, K, et al.
Published: (2014)

Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
by: Bunck, Mathijs C., et al.
Published: (2011)

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
by: Kelly, Aaron S, et al.
Published: (2012)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
by: Blevins, Thomas, et al.
Published: (2016)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
by: Wysham, C, et al.
Published: (2011)

Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study
by: Acosta, Andres, et al.
Published: (2015)

Twice-Daily Subcutaneous Injection of Kisspeptin-54 Does Not Abolish Menstrual Cyclicity in Healthy Female Volunteers
by: Jayasena, C. N., et al.
Published: (2013)

Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes
by: Schnabel, Catherine A, et al.
Published: (2006)

Exenatide extended-release; clinical trials, patient preference, and economic considerations
by: Doggrell, Sheila A
Published: (2013)

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects
by: Darpö, Börje, et al.
Published: (2013)

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
by: Tatarkiewicz, K, et al.
Published: (2013)

Exenatide-Induced Reduction in Energy Intake Is Associated With Increase in Hypothalamic Connectivity
by: Schlögl, Haiko, et al.
Published: (2013)

Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes
by: Kishimoto, Miyako, et al.
Published: (2014)

Oral Delivery of Exenatide via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate
by: Zhang, Baojie, et al.
Published: (2014)